Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Tear trough filler, using HA, offers a nonsurgical option for under-eye rejuvenation, requiring precise anatomical knowledge ...

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved ...

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular ...

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the ...

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting ...

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville ...

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company ...